Hanmi Pharmaceutical

Overview

• Industrypharmaceutical industry¹
• HeadquartersSeoul¹
• Websitewww.hanmi.co.kr
• Legal formjoint-stock company¹

See how the biggest companies compare on our leaderboards

Hanmi Pharm Co., Ltd. (Korean: 한미약품) is a South Korean pharmaceutical company that is headquartered in Seoul.³

Corporate structure

Hanmi Pharmaceutical sits at the top of its group. 3 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.

Timeline

1. 1973Founded Founded¹

Calendar

Drug trials and FDA: coming up

1. Jan 2027Phase 2 trial readout expected Phase 2 trial of HM15275 in Obese: primary completion expected Jan 2027 (ClinicalTrials.gov NCT07205900).⁵
2. Oct 2027Phase 2 trial readout expected Phase 2 trial of HM15275 in Type 2 Diabetes Mellitus: primary completion expected Oct 2027 (ClinicalTrials.gov NCT07527650).⁶

Drug trials and FDA: recently

1. Jun 26, 2026Phase 2 trial completed Phase 2 trial of HM15211 in NASH - Nonalcoholic Steatohepatitis: primary completion Jun 26, 2026, no results posted yet (ClinicalTrials.gov NCT04505436).⁷
2. Jun 16, 2026Phase 2 trial completed Phase 2 trial of HM15136 in Congenital Hyperinsulinism: primary completion Jun 16, 2026, no results posted yet (ClinicalTrials.gov NCT04732416).⁸
3. Jan 8, 2026Phase 3 trial completed Phase 3 trial of HGP2304-1, HGP2304-2 and others in Hypertension: primary completion Jan 8, 2026, no results posted yet (ClinicalTrials.gov NCT06174766).⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Stakes it holds

Hanmi Pharmaceutical has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).

• Aptose Biosciences Inc.SCHEDULE 13D/A Sep 12, 2023 to Mar 20, 2025¹⁰
• Spectrum PharmaceuticalsSC 13D Feb 1, 2022¹¹

SEC filer profile

How Hanmi Pharmaceutical is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARHanmi Pharmaceutical Co., Ltd.²
• CIK0001904921
• Incorporated inKorea, Republic of²
• Fiscal year endsDecember 31²
• Business address14, Wiryeseong-Daero, Songpa-Gu, Seoul, M5 05545²
• Phone8224108796²
• On EDGAR sinceFeb 1, 2022²
• Filings6 in all: SC 13D (2), SC 13D/A (2), 3 (1), SCHEDULE 13D/A (1)²

Links

• Websitewww.hanmi.co.kr¹
• WikipediaHanmi Pharm
• WikidataQ17095096
• SEC EDGARCIK 1904921